nodes	percent_of_prediction	percent_of_DWPC	metapath
Bupranolol—ADRB2—prostate cancer	0.91	1	CbGaD
Bupranolol—Gemfibrozil—PPARA—prostate cancer	0.00329	0.226	CrCbGaD
Bupranolol—Gemfibrozil—CYP2C19—prostate cancer	0.00107	0.0735	CrCbGaD
Bupranolol—Pirbuterol—ADRB2—prostate cancer	0.001	0.0688	CrCbGaD
Bupranolol—Levobunolol—ADRB2—prostate cancer	0.000892	0.0613	CrCbGaD
Bupranolol—Timolol—ADRB2—prostate cancer	0.000851	0.0585	CrCbGaD
Bupranolol—Terbutaline—ADRB2—prostate cancer	0.000816	0.0561	CrCbGaD
Bupranolol—Carteolol—ADRB2—prostate cancer	0.000759	0.0521	CrCbGaD
Bupranolol—Timolol—CYP2C19—prostate cancer	0.000733	0.0503	CrCbGaD
Bupranolol—Gemfibrozil—CYP3A4—prostate cancer	0.00068	0.0467	CrCbGaD
Bupranolol—Nadolol—ADRB2—prostate cancer	0.000676	0.0465	CrCbGaD
Bupranolol—Clenbuterol—ADRB2—prostate cancer	0.000653	0.0448	CrCbGaD
Bupranolol—Bopindolol—ADRB2—prostate cancer	0.000619	0.0425	CrCbGaD
Bupranolol—Salbutamol—ADRB2—prostate cancer	0.000607	0.0417	CrCbGaD
Bupranolol—Penbutolol—ADRB2—prostate cancer	0.00059	0.0405	CrCbGaD
Bupranolol—Clenbuterol—CYP1A1—prostate cancer	0.00056	0.0384	CrCbGaD
Bupranolol—Pindolol—ADRB2—prostate cancer	0.000425	0.0292	CrCbGaD
Bupranolol—Salbutamol—CYP3A4—prostate cancer	0.000332	0.0228	CrCbGaD
Bupranolol—ADRB2—GPCR ligand binding—CXCL8—prostate cancer	3.45e-05	0.000457	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—GNG5—prostate cancer	3.44e-05	0.000457	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—IGF1R—prostate cancer	3.37e-05	0.000447	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—GNG5—prostate cancer	3.37e-05	0.000447	CbGpPWpGaD
Bupranolol—ADRB3—GPCR downstream signaling—CXCL8—prostate cancer	3.35e-05	0.000445	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—JAK2—prostate cancer	3.34e-05	0.000443	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—LPL—prostate cancer	3.23e-05	0.000429	CbGpPWpGaD
Bupranolol—ADRB3—GPCR downstream signaling—IL2—prostate cancer	3.21e-05	0.000425	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—PDGFRB—prostate cancer	3.2e-05	0.000425	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—PIK3CB—prostate cancer	3.17e-05	0.000421	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—ITGB3—prostate cancer	3.12e-05	0.000414	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—CXCL8—prostate cancer	3.05e-05	0.000404	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—ERBB3—prostate cancer	3.03e-05	0.000402	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—FGFR2—prostate cancer	3.02e-05	0.000401	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PTHLH—prostate cancer	3e-05	0.000398	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—TGFBR1—prostate cancer	3e-05	0.000398	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—AKR1C3—prostate cancer	2.95e-05	0.000391	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PRKACB—prostate cancer	2.93e-05	0.000389	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PTHLH—prostate cancer	2.93e-05	0.000389	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—TGFBR1—prostate cancer	2.93e-05	0.000389	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—IL2—prostate cancer	2.91e-05	0.000386	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—TERT—prostate cancer	2.9e-05	0.000385	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—AKR1C3—prostate cancer	2.88e-05	0.000383	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PRKACB—prostate cancer	2.87e-05	0.000381	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—THBS1—prostate cancer	2.86e-05	0.000379	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PPP3CA—prostate cancer	2.86e-05	0.000379	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—ANXA1—prostate cancer	2.82e-05	0.000374	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PPP3CA—prostate cancer	2.8e-05	0.000371	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—THBS1—prostate cancer	2.8e-05	0.000371	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—HIF1A—prostate cancer	2.77e-05	0.000368	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PRKCZ—prostate cancer	2.77e-05	0.000367	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—ANXA1—prostate cancer	2.76e-05	0.000366	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—LEP—prostate cancer	2.71e-05	0.000359	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PRKCZ—prostate cancer	2.71e-05	0.000359	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—PIK3CG—prostate cancer	2.7e-05	0.000359	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CAV1—prostate cancer	2.68e-05	0.000356	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PARP1—prostate cancer	2.67e-05	0.000354	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—FGFR4—prostate cancer	2.67e-05	0.000354	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—KDR—prostate cancer	2.65e-05	0.000352	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—PIK3CG—prostate cancer	2.65e-05	0.000351	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CALCA—prostate cancer	2.64e-05	0.00035	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—FGFR4—prostate cancer	2.61e-05	0.000347	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PARP1—prostate cancer	2.61e-05	0.000347	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—ESR1—prostate cancer	2.59e-05	0.000343	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CALCA—prostate cancer	2.58e-05	0.000343	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CXCL12—prostate cancer	2.58e-05	0.000342	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—BAD—prostate cancer	2.52e-05	0.000335	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CXCL12—prostate cancer	2.52e-05	0.000335	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—PIK3CG—prostate cancer	2.46e-05	0.000326	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—APC—prostate cancer	2.44e-05	0.000324	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—PIK3CG—prostate cancer	2.44e-05	0.000324	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CASP9—prostate cancer	2.43e-05	0.000322	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—EGF—prostate cancer	2.42e-05	0.000321	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—IRS1—prostate cancer	2.42e-05	0.000321	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—PIK3CG—prostate cancer	2.4e-05	0.000319	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—PIK3CD—prostate cancer	2.38e-05	0.000315	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CASP9—prostate cancer	2.37e-05	0.000315	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PRKCQ—prostate cancer	2.35e-05	0.000312	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—NGFR—prostate cancer	2.35e-05	0.000312	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—GSK3B—prostate cancer	2.35e-05	0.000311	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—PIK3CD—prostate cancer	2.33e-05	0.000309	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—MAP3K7—prostate cancer	2.32e-05	0.000308	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—INS—prostate cancer	2.31e-05	0.000307	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PRKCQ—prostate cancer	2.3e-05	0.000305	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—NGFR—prostate cancer	2.3e-05	0.000305	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—MAP3K7—prostate cancer	2.27e-05	0.000302	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CREBBP—prostate cancer	2.27e-05	0.000301	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—IGF1—prostate cancer	2.24e-05	0.000297	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—FGF10—prostate cancer	2.23e-05	0.000297	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—EGFR—prostate cancer	2.23e-05	0.000295	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—ADRB2—prostate cancer	2.21e-05	0.000293	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—FGF10—prostate cancer	2.19e-05	0.00029	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—JAK2—prostate cancer	2.18e-05	0.000289	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—MAP2K1—prostate cancer	2.17e-05	0.000288	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—MAP2K1—prostate cancer	2.16e-05	0.000287	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—PIK3CD—prostate cancer	2.16e-05	0.000286	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—VAV3—prostate cancer	2.16e-05	0.000286	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—PIK3CD—prostate cancer	2.15e-05	0.000285	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—JAK2—prostate cancer	2.13e-05	0.000283	CbGpPWpGaD
Bupranolol—ADRB3—GPCR downstream signaling—PIK3CA—prostate cancer	2.13e-05	0.000282	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—TGFBR2—prostate cancer	2.13e-05	0.000282	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—MAP2K1—prostate cancer	2.13e-05	0.000282	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—SERPINE1—prostate cancer	2.12e-05	0.000282	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—PIK3CD—prostate cancer	2.11e-05	0.00028	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—VAV3—prostate cancer	2.11e-05	0.00028	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—KRAS—prostate cancer	2.1e-05	0.000279	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—ITPR1—prostate cancer	2.09e-05	0.000278	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—TGFBR2—prostate cancer	2.08e-05	0.000276	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—PIK3CB—prostate cancer	2.07e-05	0.000275	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—FGF2—prostate cancer	2.06e-05	0.000273	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—ITPR1—prostate cancer	2.05e-05	0.000271	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—NOS3—prostate cancer	2.03e-05	0.000269	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—PIK3CB—prostate cancer	2.03e-05	0.000269	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—IGF1R—prostate cancer	2e-05	0.000265	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—CXCL8—prostate cancer	1.99e-05	0.000264	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—JAK2—prostate cancer	1.98e-05	0.000263	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—JAK2—prostate cancer	1.97e-05	0.000262	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—IGF1R—prostate cancer	1.96e-05	0.00026	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	1.95e-05	0.000258	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—JAK2—prostate cancer	1.94e-05	0.000257	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—PIK3CA—prostate cancer	1.93e-05	0.000256	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—MDM2—prostate cancer	1.92e-05	0.000255	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—LPL—prostate cancer	1.92e-05	0.000254	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—IL2—prostate cancer	1.9e-05	0.000252	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PDGFRB—prostate cancer	1.9e-05	0.000252	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—ERBB2—prostate cancer	1.9e-05	0.000252	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—PIK3CB—prostate cancer	1.88e-05	0.00025	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—LPL—prostate cancer	1.88e-05	0.000249	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—PIK3CB—prostate cancer	1.87e-05	0.000248	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—IL2—prostate cancer	1.86e-05	0.000247	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	1.86e-05	0.000247	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—ITGB3—prostate cancer	1.85e-05	0.000246	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	1.84e-05	0.000244	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	1.81e-05	0.00024	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	1.81e-05	0.00024	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CXCL8—prostate cancer	1.8e-05	0.000239	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	1.8e-05	0.000238	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	1.79e-05	0.000238	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	1.77e-05	0.000235	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CDKN1B—prostate cancer	1.76e-05	0.000233	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	1.76e-05	0.000233	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	1.75e-05	0.000233	CbGpPWpGaD
Bupranolol—ADRB3—GPCR downstream signaling—AKT1—prostate cancer	1.74e-05	0.000231	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—IL2—prostate cancer	1.73e-05	0.000229	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CASP3—prostate cancer	1.72e-05	0.000229	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—TERT—prostate cancer	1.72e-05	0.000228	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—IL2—prostate cancer	1.72e-05	0.000228	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—IL6—prostate cancer	1.71e-05	0.000227	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—IL2—prostate cancer	1.69e-05	0.000224	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—TERT—prostate cancer	1.68e-05	0.000223	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CCND1—prostate cancer	1.68e-05	0.000222	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CTNNB1—prostate cancer	1.66e-05	0.00022	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	1.65e-05	0.000218	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—MMP9—prostate cancer	1.63e-05	0.000216	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—CDKN1A—prostate cancer	1.62e-05	0.000215	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—PTEN—prostate cancer	1.62e-05	0.000215	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	1.61e-05	0.000214	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—LEP—prostate cancer	1.61e-05	0.000213	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CAV1—prostate cancer	1.59e-05	0.000211	CbGpPWpGaD
Bupranolol—ADRB3—Signaling by GPCR—AKT1—prostate cancer	1.58e-05	0.000209	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—KDR—prostate cancer	1.57e-05	0.000209	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—LEP—prostate cancer	1.57e-05	0.000209	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CAV1—prostate cancer	1.56e-05	0.000207	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—EP300—prostate cancer	1.54e-05	0.000205	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—KDR—prostate cancer	1.54e-05	0.000204	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—ESR1—prostate cancer	1.53e-05	0.000204	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—ESR1—prostate cancer	1.5e-05	0.000199	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—SRC—prostate cancer	1.5e-05	0.000199	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—BAD—prostate cancer	1.5e-05	0.000199	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—BAD—prostate cancer	1.47e-05	0.000194	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—VEGFA—prostate cancer	1.46e-05	0.000194	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—APC—prostate cancer	1.45e-05	0.000192	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	1.45e-05	0.000192	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—STAT3—prostate cancer	1.45e-05	0.000192	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—EGF—prostate cancer	1.43e-05	0.00019	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—IRS1—prostate cancer	1.43e-05	0.00019	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	1.42e-05	0.000188	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—APC—prostate cancer	1.42e-05	0.000188	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—IRS1—prostate cancer	1.4e-05	0.000186	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—EGF—prostate cancer	1.4e-05	0.000186	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	1.39e-05	0.000185	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—INS—prostate cancer	1.37e-05	0.000182	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	1.36e-05	0.000181	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	1.34e-05	0.000178	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—MYC—prostate cancer	1.34e-05	0.000178	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—INS—prostate cancer	1.34e-05	0.000178	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—TGFB1—prostate cancer	1.34e-05	0.000178	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—IGF1—prostate cancer	1.33e-05	0.000176	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	1.32e-05	0.000175	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	1.32e-05	0.000175	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—EGFR—prostate cancer	1.32e-05	0.000175	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—IGF1—prostate cancer	1.3e-05	0.000172	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	1.29e-05	0.000172	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	1.28e-05	0.00017	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	1.28e-05	0.000169	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	1.26e-05	0.000168	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	1.26e-05	0.000167	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	1.26e-05	0.000167	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	1.25e-05	0.000166	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	1.25e-05	0.000166	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—KRAS—prostate cancer	1.24e-05	0.000165	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	1.24e-05	0.000164	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	1.23e-05	0.000164	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	1.22e-05	0.000162	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—FGF2—prostate cancer	1.22e-05	0.000162	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—NOS3—prostate cancer	1.2e-05	0.00016	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—FGF2—prostate cancer	1.19e-05	0.000158	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—NOS3—prostate cancer	1.18e-05	0.000156	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—JAK2—prostate cancer	1.17e-05	0.000155	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	1.15e-05	0.000152	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—JAK2—prostate cancer	1.14e-05	0.000152	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—MDM2—prostate cancer	1.14e-05	0.000152	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—PIK3CA—prostate cancer	1.14e-05	0.000151	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	1.13e-05	0.000149	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	1.12e-05	0.000149	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—MDM2—prostate cancer	1.12e-05	0.000148	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	1.11e-05	0.000147	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—TP53—prostate cancer	1.1e-05	0.000147	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	1.1e-05	0.000146	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	1.09e-05	0.000144	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	1.07e-05	0.000142	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	1.04e-05	0.000139	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	1.04e-05	0.000138	CbGpPWpGaD
Bupranolol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	1.03e-05	0.000137	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CASP3—prostate cancer	1.02e-05	0.000136	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—IL2—prostate cancer	1.02e-05	0.000135	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	1.02e-05	0.000135	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—IL6—prostate cancer	1.02e-05	0.000135	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—IL6—prostate cancer	1.01e-05	0.000134	CbGpPWpGaD
Bupranolol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	1.01e-05	0.000134	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CASP3—prostate cancer	1e-05	0.000133	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—IL2—prostate cancer	9.99e-06	0.000132	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CCND1—prostate cancer	9.95e-06	0.000132	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—IL6—prostate cancer	9.94e-06	0.000132	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	9.85e-06	0.000131	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CCND1—prostate cancer	9.73e-06	0.000129	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—MMP9—prostate cancer	9.66e-06	0.000128	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	9.64e-06	0.000128	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	9.63e-06	0.000128	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PTEN—prostate cancer	9.6e-06	0.000127	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—MMP9—prostate cancer	9.45e-06	0.000125	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	9.42e-06	0.000125	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PTEN—prostate cancer	9.4e-06	0.000125	CbGpPWpGaD
Bupranolol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	9.37e-06	0.000124	CbGpPWpGaD
Bupranolol—ADRB3—Signaling Pathways—AKT1—prostate cancer	9.33e-06	0.000124	CbGpPWpGaD
Bupranolol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	9.17e-06	0.000122	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—EP300—prostate cancer	9.16e-06	0.000122	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—EP300—prostate cancer	8.96e-06	0.000119	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—SRC—prostate cancer	8.91e-06	0.000118	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—SRC—prostate cancer	8.71e-06	0.000116	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	8.67e-06	0.000115	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—STAT3—prostate cancer	8.59e-06	0.000114	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	8.49e-06	0.000113	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—STAT3—prostate cancer	8.4e-06	0.000111	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—MYC—prostate cancer	7.98e-06	0.000106	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	7.96e-06	0.000106	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—MYC—prostate cancer	7.81e-06	0.000104	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—EGFR—prostate cancer	7.81e-06	0.000104	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	7.79e-06	0.000103	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—EGFR—prostate cancer	7.64e-06	0.000101	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—KRAS—prostate cancer	7.37e-06	9.79e-05	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—KRAS—prostate cancer	7.21e-06	9.57e-05	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	6.78e-06	8.99e-05	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	6.63e-06	8.79e-05	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—TP53—prostate cancer	6.55e-06	8.7e-05	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—TP53—prostate cancer	6.41e-06	8.51e-05	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—IL6—prostate cancer	6e-06	7.96e-05	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—IL6—prostate cancer	5.87e-06	7.79e-05	CbGpPWpGaD
Bupranolol—ADRB1—Signaling Pathways—AKT1—prostate cancer	5.54e-06	7.34e-05	CbGpPWpGaD
Bupranolol—ADRB2—Signaling Pathways—AKT1—prostate cancer	5.41e-06	7.18e-05	CbGpPWpGaD
